🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInternationalSouth Korea Ozempic availability — Samsung Medical Center experience Page 4

South Korea Ozempic availability — Samsung Medical Center experience

hyun_seoul Tue, Jun 2, 2026 at 11:28 PM 25 replies 525 viewsPage 4 of 5
DebRD_ATL
Senior Member
1,678
7,890
Feb 2024
Atlanta, GA
Jun 4, 2026 at 4:31 AM#16

From the other side of the consultation, briefly. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.

36 11BiostatsBrad, PeptideSynthNJ, Dr.KarenChen and 33 others
Reply Quote Save Share Report
DadBodDave
Member
187
923
Nov 2024
Ohio
Jun 4, 2026 at 9:10 AM#17
DebRD_ATL said:
The mechanism and the magnitude are separate questions.

This is where I part company with the consensus forming above. Pushing back on the anecdote-stacking. Twenty people reporting the same thing is twenty samples from the same self-selected pool, not twenty independent confirmations.

35 10JenMemphis, pat_auckland, Dr.GastroMayo and 32 others
Reply Quote Save Share Report
LindaRN_retired
Member
189
890
Dec 2024
Sarasota, FL
Jun 4, 2026 at 1:50 PM#18
DebRD_ATL said:
The mechanism and the magnitude are separate questions.

That is correct as far as it goes, and here is where it stops going. Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak. People who dose late are not losing a peak, they are letting the trough fall, and the appetite effect tracks the trough.

34 9amsterdam_pete, LondonLisa, mike_nyc and 31 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
GenomicsKate
Member
345
1,890
Oct 2024
Cambridge, MA
Jun 4, 2026 at 6:29 PM#19
DebRD_ATL said:
The mechanism and the magnitude are separate questions.

Bookmarking. The distinction being drawn above is the one nobody else makes. Adding it to my notes with a link back to this thread.

Last edited: Jun 4, 2026 at 11:29 PM
33 8Dr.PeteFamMed, claudia_zurich, nancy_portland and 30 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Jun 4, 2026 at 11:08 PM#20

Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful. Tagging this one for the weekly digest.

Last edited: Jun 5, 2026 at 1:08 AM
11 11PurityPaulOR, MaxMetOK, MounjBrad and 8 others
Reply Quote Save Share Report

Similar Threads

EU EMA compounding guidance — 2026 regulatory update9 replies
UK NHS GLP-1 prescribing — NICE TA875 and access guide7 replies
Australian TGA scheduling changes — peptide access 20268 replies
Canadian GLP-1 coverage — provincial formulary comparison6 replies
Purchasing GLP-1 in Mexico — legality, quality, and safety concerns6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register